An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

Abstract Background The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients dur...

Descripció completa

Dades bibliogràfiques

Autors principals:	Eva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, Damalie Nalwanga, Barbara Castelnuovo, Abdu Musubire, Agnes Kiragga, Mohammed Lamorde, Rosalind Parkes- Ratanshi
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2019-03-01
Col·lecció:	BMC Infectious Diseases
Matèries:	Second-line antiretroviral First-line failure Atazanavir Lopinavir
Accés en línia:	http://link.springer.com/article/10.1186/s12879-019-3907-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!